An SME perspective on the MAA process (including e-dossier preparation and submission)

Size: px
Start display at page:

Download "An SME perspective on the MAA process (including e-dossier preparation and submission)"

Transcription

1 An SME perspective on the MAA process (including e-dossier preparation and submission) Session 4: Regulatory issues in the run-up to dossier submission (part II)

2 Outline 1. Introduction 2. MAA process and SME Office 3. Unique challenges 4. Conclusion 2

3 Introduction 3

4 SME Initiative: SME Office & Incentives Waiver of MedDRA licensing fee Regulatory Assistance (administrative, procedural) Financial incentives Translation assistance Conditional fee exemption SME Office Inclusion in SME register Support for post-marketing autorisation activities Support before MAA submission 4

5 How are the current incentives helpful to navigate the MAA process? 5

6 Regulatory Challenges of MAA Process for SME Numerous procedures Need understanding of regulatory review process and its complexity Several committees involved during development Numerous contacts (PIP, ODD; MAA, SME, etc.) Numerous documents Multiplicity of dossier requirements No or limited in house regulatory expertise No or limited knowledge of dossier content and format For PIP, requirements to submit per product Regulated environment No or limited in house knowledge of requirements, regulations, guidelines Limited information about changing regulatory requirements and legislation 6

7 Navigating the European Regulatory Landscape The EMA s scientific committees Protocol Assistance SAWP PDCO Paediatric Requirements Opinion on Marketing Autorisation Opinion on Orphan Designation & Maintenance COMP CHMP Biologics WP Support to dossier evaluation SME Office CAT PRAC Quality WP ( ) Support for navigating European procedures Designation Expertise / Product Classification Risk Management & Pharmacovigilance Considerations 7

8 Diversity of Regulatory Interactions in Europe Early stage Clinical development MAA pre -sub MAA review Post MA + PhV NCA C H M P COMP PDCO SAWP CAT PDCO PDCO SAWP SME Office provides support at each step of development and helps understanding EMA functioning PDCO PRAC COMP CAT EC CHMP PRAC. Supported by: PRAC QWP BWP SWP Non-clinical WG ( ) PDCO 8

9 Marketing Authorization Process in EU A step-wise approach Orphan designation by COMP/EC Orphan Designation Procedure* Paediatric Investigation Plan by PDCO/EU Paediatric requirement (PIP, classwaiver) Protocol Assistance by CHMP (SAWP) Protocol Assistance Procedure/ follow up Re-examination of Orphan designation opinion by COMP* PIP Compliance Check Centralized Procedure CHMP Opinion EC Decision Marketing Authorization Post-marketing commitments SME Office CAT PRAC Post-marketing activities * If applicable 9

10 Pre-MAA Activities Accelerated Assessment Procedure request Eligibility for CP request Letter of intent to submit Pre-submission meeting request Rapporteur / Co-rapporteur meeting requests Compliance check ATC code request Invented name request Fee reduction request SME Office is providing helpful support Soliris case: frequent informal interactions 10

11 MAA Accelerated Assessment Procedure Pre-submission meeting 6 month before submitting Meetings with Rapporteur to discuss draft questions Clarification Meeting Clock-stop 1 month D155-D177 Product Translation Review SOLIRIS case M1 M3 M5 M7 M9 M11 MAA submission Validation Period M2 D1 Start of Procedure M4 D80 Draft Assessment Reports EMA support via Project Team Leader M6 D120 LoQ (Technical PIQ comments) + Start of inspection procedure Submission Answers to LoQ D121 Re-start of Procedure M8 D135 Draft Assessment Reports D150 Oral Explanation and/or Opinion D155 Translation of Product Information in all EU languages M10 D217 EC Approval D177 Final versions in all languages SME Office support 11

12 Product Information Translation D1 to D155 Product Information Review (English version) D150 to D155 Generation of translated versions D155 to D177 Final draft submitted with initial MAA First set of comments D120 (+ PIQ comments) Revised version submitted at D121 Second review D frequent interactions with EMA/Project Manager Final text adopted D150 (positive opinion) 22 European languages + IS and NO (+ CR) SME Office support Translation Review by Member States 12

13 Remaining Challenges Post-Authorization National steps to be performed: European Article Numbering code Blue-box Risk Management Plan implementation Time- and resources-consuming process, lots of variability, lack of up to date information No specific support to date to expedite national process (guidance information provided in SME User Guide) Navigating post-marketing regulations Close regulatory surveillance needed SME Office publication 13

14 Remaining Challenges Post-Authorization SME support in monitoring newly released or changed regulatory requirements 14

15 How are SMEs handling the electronic submission requirement? 15

16 Fundamentals of ectd ectd Offers a standard format of submission to different agencies Improves lifecycle management Enhances the transfer of information between sponsor, outsourcing partners and authorities Offers ability to rapidly find the components, re-use some documents Allows transparency of changes/variations amending the MAA dossier 16

17 However, ectd requirement Additional complexity Specific technical knowledge required, staff training, implementation of tools to meet e-submission criteria Strict compliance with defined formatting requirements required for a successful validation 17

18 XML backbone: Different Components Meta data Leaf file Lifecycle management 18

19 ectd Basic Process Flow Applicant Authoring (in or outside edm) Verification Review (in or outside edm) Compilation in esubmission Management System Upload Metadata Operation type management Hyperlinks setting Validation Publishing Submission Validator software available for free (EURSValidator) 19

20 ectd Looking into the Future Requirements will continue to change / mount leading to refinement and improvement of ectd specification and harmonization of the standards Adequate processes required to keep pace with Regulation changes e-submission expertise CRITICAL Interest of managing ectd dossier using a web-based approach working in a cloud environment 20

21 Different Approaches to Consider for SMEs Outsourcing solution or in-house production, which direction to go? Critical components to be considered: ectd ready documents fully compliant ectd document management system 21

22 Different Approaches to Consider for SMEs Advantages of OUTSOURCING To avoid the purchase and maintenance of expensive tools To avoid the training of employees not familiar with the production of ectd-compliant dossiers To take advantage of global experience built on a large client database To avoid delays in producing high quality work 22

23 Different Approaches to Consider for SMEs Drawbacks of OUTSOURCING Intensive preparatory work cannot be avoided Loss of business control of the company s operations Cost (or/and hidden cost) Total dependence on the outsourcing company Know-how not developed within the company Assure that each individual vendor involved in document preparation can deliver compliant-ectd documents as part of their services 23

24 Different Approaches to Consider for SMEs Is the IN-HOUSE production a right direction to go for SMEs? Specific considerations: Can you hire Regulatory Operations professionals? Acquisition of viewing software to enable people to review submission List all Software to purchase for ectd compilation & consider their costs Templates for authors Desktop tools to create and manipulate PDF files Publishing software to create & validate the xml backbone 24

25 Different Approaches to Consider for SMEs What about a Combined Approach (Hybrids)? Examples: Develop in house ectd document templates & share them Outsource fully integrated and compliant document management system Outsource first submission, bring the rest in-house Services à la carte : chose vendors and consultants according to specific needs (networking solution) In-house publisher, with contractors for document formatting In-house formatting, with contract publishers 25

26 Conclusions MAA process currently well supported by EMA/SME Office SME initiative has been helpful supporting Soliris review process & supporting SMEs in general Specific considerations for ectd: Technical requirements increase dossier preparation complexity Hybrid solution may be the right answer 26

27 Thank you for your attention

Authorisation of ATMPs in EU: routes to facilitate prompt availability for patients.

Authorisation of ATMPs in EU: routes to facilitate prompt availability for patients. Authorisation of ATMPs in EU: routes to facilitate prompt availability for patients. This presentation only reflects the views of its author and does not necessarily reflect the opinion of the Commission

More information

Issues identified by stakeholders: follow-up from EMA s ATMP workshop

Issues identified by stakeholders: follow-up from EMA s ATMP workshop 2 February 2017 EMA/48099/2017 Human Medicines Research and Development Support Division On 27 May 2016 EMA hosted a workshop 1 aimed to foster ATMP development and enable expanded patient access in the

More information

Scientific advice and its impact on marketing authorisation application reviews

Scientific advice and its impact on marketing authorisation application reviews Scientific advice and its impact on marketing authorisation application reviews SME info day: Tools to support innovative medicines development and early access Presented by Jan Regnström, MD, PhD Scientific

More information

Clinical Development and enabling Regulatory Steps: How to obtain ODD and Scientific Advice at EMA

Clinical Development and enabling Regulatory Steps: How to obtain ODD and Scientific Advice at EMA Clinical Development and enabling Regulatory Steps: How to obtain ODD and Scientific Advice at EMA TELETHON Convention, Riva del Garda (TN) 15 March 2017 Michela Gabaldo Head Alliance Management & Regulatory

More information

How are medicines evaluated at the EMA

How are medicines evaluated at the EMA How are medicines evaluated at the EMA Presented by: Nathalie Bere Patient interaction / Stakeholders and communication Division An agency of the European Union The European System Centralised Procedure

More information

Marketing Authorisation Routes in the EU

Marketing Authorisation Routes in the EU Marketing Authorisation Routes in the EU The EU medicines regulatory system and the European Medicines Agency: an introduction for international regulators and non-governmental organisations 18 September

More information

Content. Introduction: Approval of ATMPs. Support to ATMP developers. Role of EMA and National Competent Authorities

Content. Introduction: Approval of ATMPs. Support to ATMP developers. Role of EMA and National Competent Authorities Content Introduction: Role of EMA and National Competent Authorities Approval of ATMPs What are ATMPs? Centralised procedure Support to ATMP developers 1 Introductory statements This talk is on marketing

More information

ORPHAN DESIGNATION BY THE EMA. Paillard Juliette M2 AREIPS 15/11/2016

ORPHAN DESIGNATION BY THE EMA. Paillard Juliette M2 AREIPS 15/11/2016 ORPHAN DESIGNATION BY THE EMA Paillard Juliette M2 AREIPS 15/11/2016 Legal basis 1. Legal background 2. Criteria SUMMARY Procedure 1. Prior to the submission 2. Submission and validation 3. Evaluation

More information

Priority Medicines (PRIME) scheme

Priority Medicines (PRIME) scheme Priority Medicines (PRIME) scheme DGRA Congress, Bonn, 15 June 2016 Presented by Christelle Bouygues Regulatory Affairs Officer An agency of the European Union Outline Why Prime? What is PRIME? PRIME Eligibility

More information

Workshop on the review of product information at the EMA by patients

Workshop on the review of product information at the EMA by patients Workshop on the review of product information at the EMA by patients EURORDIS Summer school 2015 Nathalie Bere interaction - Stakeholder and Communication Division An agency of the European Union What

More information

Functioning of the PRAC

Functioning of the PRAC Functioning of the PRAC Sixth Stakeholders forum on the implementation of the new Pharmacovigilance legislation, November 8 th 2012 Presented by: Almath Spooner Vice Chair, Pharmacovigilance Risk Assessment

More information

Introduction to the European Medicines Agency

Introduction to the European Medicines Agency Introduction to the European Medicines Agency EFA training for patient experts on allergy, asthma and COPD on getting involved with the EMA, 18 February 2014 Presented by: Isabelle Moulon Head of patients

More information

The role of patients at the EMA

The role of patients at the EMA The role of patients at the EMA Nathalie Bere Patient relations coordinator / European Medicines Agency An agency of the European Union What is the European Medicines Agency (EMA) The EMA is the EU regulatory

More information

arena that impact on clinical development

arena that impact on clinical development RESEARCH DEVELOPMENT Changes in the regulatory arena that impact on clinical development 23 May 2011 Agenda Voluntary Harmonisation Procedure PIP and Paediatric requirements Changes to EudraCT and European

More information

Submission of comments on COMMISSION NOTICE ON THE APPLICATION OF ARTICLES 3, 5 AND 7 OF REGULATION (EC) NO 141/2000 ON ORPHAN MEDICINAL PRODUCTS

Submission of comments on COMMISSION NOTICE ON THE APPLICATION OF ARTICLES 3, 5 AND 7 OF REGULATION (EC) NO 141/2000 ON ORPHAN MEDICINAL PRODUCTS Ref. Ares(2016)807620-16/02/2016 15 February 2016 Submission of comments on COMMISSION NOTICE ON THE APPLICATION OF ARTICLES 3, 5 AND 7 OF REGULATION (EC) NO 141/2000 ON ORPHAN MEDICINAL PRODUCTS Response

More information

EU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective

EU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective EU scientific regulatory support mechanisms and initiatives for innovation in drug development: the EMA perspective FAMHP Workshop, Brussels, 2 nd May 2016 Presented by Zahra Hanaizi Product Development

More information

How CAT Works: Regulatory Process, Patient Contribution and Outcomes

How CAT Works: Regulatory Process, Patient Contribution and Outcomes www.eurordis.org How CAT Works: Regulatory Process, Patient Contribution and Outcomes Michele Lipucci Di Paola AVLT/EURORDIS CAT/EMA Patient Representative michele.lipucci@eurordis.org EURORDIS MEMBERSHIP

More information

Cooperation between regulators in Africa experience from the EU system. Pretoria Dr Tomas Salmonson. Chair, CHMP, EMA, UK

Cooperation between regulators in Africa experience from the EU system. Pretoria Dr Tomas Salmonson. Chair, CHMP, EMA, UK Cooperation between regulators in Africa experience from the EU system Pretoria 2015 Dr Tomas Salmonson Chair, CHMP, EMA, UK Outline of presentation Introduction the European context European Medicines

More information

Procedure management of variations

Procedure management of variations Procedure management of variations Process changes made and current challenges Presented by Alberto Ganan and Iordanis Gravanis on 24 April 2015 Procedure Management Department An agency of the European

More information

-Regulation (EC) No.1394/2007 -Regulation (EC) No. 668/2009

-Regulation (EC) No.1394/2007 -Regulation (EC) No. 668/2009 Introduction to Advanced Therapy Medicinal Products Regulation -Regulation (EC) No.1394/2007 -Regulation (EC) No. 668/2009 -Directive 2009/120/EC Dr. Maura O Donovan F.R.C.O.G. MA MD M.R.C.P.I. CAT member

More information

Engagement with stakeholders

Engagement with stakeholders Engagement with stakeholders 2 nd International Awareness Session - The EU medicines regulatory system and the European Medicines Agency Presented by Juan Garcia Burgos and Marie-Helene Pinheiro on 8 March

More information

Key concepts of the paediatric regulation and latest developments

Key concepts of the paediatric regulation and latest developments Key concepts of the paediatric regulation and latest developments Paolo Tomasi, M.D. Ph.D. Head of Paediatric Medicines European Medicines Agency Presented by: Paolo Tomasi An agency of the European Union

More information

Legislative Framework and Scientific Guidance in European Assessment

Legislative Framework and Scientific Guidance in European Assessment Legislative Framework and Scientific Guidance in European Assessment Riccardo Luigetti Quality Assessors Training London 26 October 2009 1 Content of the presentation Scientific guidelines Other related

More information

EUCERD RECOMMENDATION FOR A

EUCERD RECOMMENDATION FOR A EUCERD RECOMMENDATION FOR A CAVOMP INFORMATION FLOW RECOMMENDATION OF THE EUROPEAN UNION COMMITTEE OF EXPERTS ON RARE DISEASES TO THE EUROPEAN COMMISSION AND THE MEMBER STATES ON IMPROVING INFORMED DECISIONS

More information

Supporting Innovation through Scientific Advice

Supporting Innovation through Scientific Advice Supporting Innovation through Scientific Advice PEARRL Regulatory Science Symposium, 21 st June 2017, University College Cork HPRA Dr Peter Kiely Disclaimer All views expressed in this presentation are

More information

Centralised Procedure and Scientific Advice: an Overview

Centralised Procedure and Scientific Advice: an Overview Centralised Procedure and Scientific Advice: an Overview Andrea Laslop Head of Scientific Office AGES Medizinmarktaufsicht AGES Vienna 30/01/2018 Austrian Federal Office for Safety in Health Care www.basg.gv.at

More information

EMA/CAT support to ATMP developers

EMA/CAT support to ATMP developers EMA/CAT support to ATMP developers CAT-ISCT Workshop: Challenge and opportunities for the successful development and approval of Advanced Therapy Medicinal Products. Presented by Patrick Celis on 25 September

More information

Overview of recent changes in the centralised procedure

Overview of recent changes in the centralised procedure Overview of recent changes in the centralised procedure 2 nd Industry stakeholder platform, 9 November 2015 Presented by: Michael Berntgen Head of Scientific & Regulatory Management Department An agency

More information

GxP Inspections within the Centralised Procedure. Brendan Cuddy Inspections Sector

GxP Inspections within the Centralised Procedure. Brendan Cuddy Inspections Sector GxP Inspections within the Centralised Procedure Brendan Cuddy Inspections Sector Agenda Introduction to work of the Inspections Sector GxP Inspections within the centralised procedure Regulatory framework

More information

FIVE SECRETS OF GREAT PUBLISHERS

FIVE SECRETS OF GREAT PUBLISHERS WHITEPAPER FIVE SECRETS OF GREAT PUBLISHERS Adair Turner Principal Consultant, Director, Head of Regulatory Operations North America adair.turner@pharmalex.com Adair has 15 years of experience in Regulatory

More information

Applying for EU marketing authorisation. For medicinal products for human use. An agency of the European Union

Applying for EU marketing authorisation. For medicinal products for human use. An agency of the European Union Applying for EU marketing authorisation For medicinal products for human use An agency of the European Union Medicines can be authorised throughout the EU by means of a single application procedure. The

More information

Regulatory Affairs: Study Report of New Drug Registration Process in European Union

Regulatory Affairs: Study Report of New Drug Registration Process in European Union 95 Review Article Regulatory Affairs: Study Report of New Drug Registration Process in European Union Yogeshkumar B. Viradiya*, Manoj B. Dagwar, Swapnil T. Lanjewar Department of Regulatory Affairs, Institute

More information

The European Medicines Agency: A well-established Agency of the EU protecting human and animal health for all EU citizens

The European Medicines Agency: A well-established Agency of the EU protecting human and animal health for all EU citizens 14 July 2016 EMA/457243/2016 The European Medicines Agency: A well-established Agency of the EU protecting human and animal health for all EU citizens 1. Who we are The European Medicines Agency (EMA)

More information

European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure

European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure 11 December 2017 EMA/821278/2015 Human Medicines Research and Development Support European Medicines Agency pre-authorisation procedural advice for users of the This integrated version has been created

More information

EudraCT database and EU Clinical Trials Register (EU-CTR)

EudraCT database and EU Clinical Trials Register (EU-CTR) EudraCT database and EU Clinical Trials Register (EU-CTR) Presented by: Laura Pioppo Compliance and Inspection Sector PCWP and HCP WG 16.06.2011 An agency of the European Union Definitions information

More information

DRAFT Proposal for a Repurposing Framework. EFPIA and Medicines for Europe 30 April 2018

DRAFT Proposal for a Repurposing Framework. EFPIA and Medicines for Europe 30 April 2018 DRAFT Proposal for a Repurposing Framework EFPIA and Medicines for Europe 30 April 2018 1 Framework for Repurposing* Key elements to consider For a new use for an off-patent compound Champion** puts forward

More information

Guidance on preparing for Brexit in the centralised procedure

Guidance on preparing for Brexit in the centralised procedure Guidance on preparing for Brexit in the centralised procedure SME info day: Regulatory toolbox for medicines and combined devices developers Presented by Leonor Enes on 26 October 2018 SME Office, Stakeholders

More information

PRIority MEdicines (PRIME)

PRIority MEdicines (PRIME) PRIority MEdicines (PRIME) Support to development of priority medicines for unmet medical needs. EuropaBIO information day, 15 October 2015 Jordi Llinares, Head of product development scientific support.

More information

PRIME. 7 th STAMP meeting Brussels, 27 th June Presented by Sonia Ribeiro Head of Regulatory Affairs Office, Human Medicines Evaluation Division

PRIME. 7 th STAMP meeting Brussels, 27 th June Presented by Sonia Ribeiro Head of Regulatory Affairs Office, Human Medicines Evaluation Division PRIME 7 th STAMP meeting Brussels, 27 th June 2017 Presented by Sonia Ribeiro Head of Regulatory Affairs Office, Human Medicines Evaluation Division An agency of the European Union Overview of one-year

More information

Roles and responsibilities of members and alternates, rapporteur and peer reviewers, experts and observers of the Paediatric Committee (PDCO)

Roles and responsibilities of members and alternates, rapporteur and peer reviewers, experts and observers of the Paediatric Committee (PDCO) Last revision: 16 September 2010 EMA/537415/2008 Human Medicines Development and Evaluation Roles and responsibilities of members and alternates, rapporteur and peer reviewers, experts and observers of

More information

European Medicines Agency post-authorisation procedural advice for users of the centralised procedure

European Medicines Agency post-authorisation procedural advice for users of the centralised procedure 11 December 2017 EMEA-H-19984/03 Rev. 75 Human Medicines Evaluation Division European Medicines Agency post-authorisation procedural advice for users of the This integrated version has been created for

More information

European Medicines Agency post-authorisation procedural advice for users of the centralised procedure

European Medicines Agency post-authorisation procedural advice for users of the centralised procedure June 2013 EMEA-H-19984/03 Rev 30 Patient Health Protection European Medicines Agency post-authorisation procedural advice for users of the centralised procedure This integrated version has been created

More information

EMEA/AD/258: Head of Sector Pharmacovigilance and Risk Management of Medicinal Products for Human Use (AD9).

EMEA/AD/258: Head of Sector Pharmacovigilance and Risk Management of Medicinal Products for Human Use (AD9). EMEA/AD/258: Head of Sector Pharmacovigilance and Risk Management of Medicinal Products for Human Use (AD9). Responsible, under the Head of Unit for the Post-Authorisation Evaluation of Medicinal Products

More information

Module 1: Administrative information Application form

Module 1: Administrative information Application form 7 September 2017 CMDh/332/2017/Rev.1 User guide for the electronic application form for a Marketing Authorisation Purpose and general rules This User guide has been prepared in order to facilitate the

More information

GxP Inspections within the Centralised Procedure

GxP Inspections within the Centralised Procedure GxP Inspections within the Centralised Procedure Brendan Cuddy Inspections Sector 2nd EMEA Workshop for Micro, Small and Medium- Sized Enterprises (SMEs) Focus on Quality Agenda Introduction to work of

More information

Pediatric drug development - do we need a PIP so early in development? American versus European approach

Pediatric drug development - do we need a PIP so early in development? American versus European approach Pediatric drug development - do we need a PIP so early in development? American versus European approach Angelika Joos Executive Director, Global Regulatory Policy Merck Sharp & Dohme (Europe) Inc., Brussels

More information

QUESTIONS AND ANSWERS ON THE PAEDIATRIC REGULATION (REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL (EC) No 1901/2006, AS AMENDED)

QUESTIONS AND ANSWERS ON THE PAEDIATRIC REGULATION (REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL (EC) No 1901/2006, AS AMENDED) QUESTIONS AND ANSWERS ON THE PAEDIATRIC REGULATION (REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL (EC) No 1901/2006, AS AMENDED) ARTICLE 45 & 46 October 2007 Revision 4, November 2008 Question

More information

EC REVIEW OF THE ATMP REGULATION CELL THERAPY CATAPULT RESPONSES

EC REVIEW OF THE ATMP REGULATION CELL THERAPY CATAPULT RESPONSES EC REVIEW OF THE ATMP REGULATION CELL THERAPY CATAPULT RESPONSES 1 Introduction It is clear from the very small number of MAA approved to date that the registration process for ATMPs is complex and not

More information

Orphan Drug Development Strategic considerations

Orphan Drug Development Strategic considerations Orphan Drug Development Strategic considerations Jan van Emous Regulatory Affairs Director Europe PGH Genzyme, a Sanofi company www.genzyme.com jan.vanemous@genzyme.com Regulatory Intelligence Orphan Drug

More information

Orphan Drug Designation within the Development Strategy

Orphan Drug Designation within the Development Strategy Case Report imedpub Journals http://wwwimedpub.com Journal of Rare Disorders: Diagnosis & Therapy Vol. 1 No. 2:12 DOI: 10.21767/2380-7245.100012 Orphan Drug Designation within the Development Strategy

More information

ICH and EU regulatory framework and the role of the European Medicines Agency (EMA)

ICH and EU regulatory framework and the role of the European Medicines Agency (EMA) ICH and EU regulatory framework and the role of the European Medicines Agency (EMA) GCC Workshop on Similar Biological Medicinal Products (Biosimilars) 19-20 April 2011, Riyadh Falk Ehmann MD, PhD, MSc

More information

Accelerated Approvals

Accelerated Approvals Accelerated Approvals An Industry Perspective Kumeshnie Padayachee University of Pretoria 09 September 2015 Table of Contents ZA Expedite Review Process Fast Track Overview of FDA Expedited Pathways: Focus

More information

Commission notice on the application of Articles 3, 5 and 7 of Regulation (EC) No 141/2000 on orphan medicinal products (2016/C 424/03)

Commission notice on the application of Articles 3, 5 and 7 of Regulation (EC) No 141/2000 on orphan medicinal products (2016/C 424/03) 18.11.2016 EN Official Journal of the European Union C 424/3 Commission notice on the application of Articles 3, 5 and 7 of Regulation (EC) No 141/2000 on orphan medicinal products (2016/C 424/03) A. INTRODUCTION

More information

Work programme Adopted by the Management Board on 18 December December 2014 EMA/773839/2014 Rev. 1 Management Board

Work programme Adopted by the Management Board on 18 December December 2014 EMA/773839/2014 Rev. 1 Management Board 18 December 2014 EMA/773839/2014 Rev. 1 Management Board Work programme 2015 Adopted by the Management Board on 18 December 2014 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

1. Aim. 2. Who needs to complete an e-doi?

1. Aim. 2. Who needs to complete an e-doi? 24 April 2015 EMA/627294/2014, Rev. 1 European Medicines Agency Procedural guidance on inclusion of declared interests in the European Medicines Agency s electronic declaration of interests form (for scientific

More information

Chin Koerner Executive Director US Regulatory and Development Policy

Chin Koerner Executive Director US Regulatory and Development Policy Chin Koerner Executive Director US Regulatory and Development Policy Novartis Pharmaceuticals Corporation 1700 Rockville Pike Suite 510 Rockville, MD 20852 Tel 301.468.5607 Fax 301.468.5614 Email: Chin.Koerner@novartis.com

More information

Deal Making and Product Development in Europe: Changes and Trends You Need to Know About: Regulatory Strategy

Deal Making and Product Development in Europe: Changes and Trends You Need to Know About: Regulatory Strategy Deal Making and Product Development in Europe: Changes and Trends You Need to Know About: Regulatory Strategy Lincoln Tsang Amanda Wearing Jeremy Willcocks November 19, 2004 November 19, 2004 Slide 1 Key

More information

Review of EU Clinical Trial Directive. 15 May 2012 Mike Beckers Sidley Austin LLP, Brussels

Review of EU Clinical Trial Directive. 15 May 2012 Mike Beckers Sidley Austin LLP, Brussels BEIJING BRUSSELS CHICAGO DALLAS FRANKFURT GENEVA HONG KONG LONDON LOS ANGELES NEW YORK PALO ALTO SAN FRANCISCO SHANGHAI SINGAPORE SYDNEY TOKYO WASHINGTON, D.C. Review of EU Clinical Trial Directive 15

More information

WRITTEN SUBMISSION ON THE OPERATION OF THE CLINICAL TRIALS DIRECTIVE (DIRECTIVE 2001/20/EC) AND PERSPECTIVES FOR THE FUTURE

WRITTEN SUBMISSION ON THE OPERATION OF THE CLINICAL TRIALS DIRECTIVE (DIRECTIVE 2001/20/EC) AND PERSPECTIVES FOR THE FUTURE WRITTEN SUBMISSION ON THE OPERATION OF THE CLINICAL TRIALS DIRECTIVE (DIRECTIVE 2001/20/EC) AND PERSPECTIVES FOR THE FUTURE ECRIN (European Clinical Research Infrastructures Network) EORTC (European Organization

More information

Overview of the new pharmacovigilance legislation

Overview of the new pharmacovigilance legislation Overview of the new pharmacovigilance legislation SME workshop: 19 April 2012 Dr Peter Arlett Head, Pharmacovigilance and Risk Management EMA An agency of the European Union In this talk: New legislation

More information

Interested parties (organisations or individuals) that commented on the draft document as released for consultation.

Interested parties (organisations or individuals) that commented on the draft document as released for consultation. 17 th February 2010 EMA/CAT/106109/2010 Committee for Advanced Therapies (CAT) Overview of comments received on 'Procedural Advice on the Provision of Scientific Recommendation on Classification of Advanced

More information

EU regulatory tools for expedited antibacterial development programmes

EU regulatory tools for expedited antibacterial development programmes EU regulatory tools for expedited antibacterial development programmes Expediting antibacterial development: core lessons key tools for a rocky road, ECCMID 2018, Madrid Presented by Marco Cavaleri on

More information

Guideline on the processing of renewals in the centralised procedure

Guideline on the processing of renewals in the centralised procedure 22 June 2012 EMEA/CHMP/2990/00 Rev.4 Committee for Human Medicinal Products (CHMP) Guideline on the processing of renewals in the centralised procedure Transmission to CPMP November 2000 Release for consultation

More information

Guideline on the processing of renewals in the centralised procedure

Guideline on the processing of renewals in the centralised procedure 22 June 2012 EMEA/CHMP/2990/00 Rev.4 Committee for Human Medicinal Products (CHMP) Guideline on the processing of renewals in the centralised procedure Transmission to CPMP November 2000 Release for consultation

More information

Work programme July 2016 EMA/92499/2016 Rev. 1 1 Executive Director. 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

Work programme July 2016 EMA/92499/2016 Rev. 1 1 Executive Director. 30 Churchill Place Canary Wharf London E14 5EU United Kingdom 5 July 2016 EMA/92499/2016 Rev. 1 1 Executive Director 1 Procurement plan added (annex 5) 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20

More information

Stakeholders engagement

Stakeholders engagement Stakeholders engagement The EU medicines regulatory system and the European Medicines Agency: an introduction for international regulators and non-governmental organisations 18-19 September 2017 Presented

More information

Medicines for Children

Medicines for Children ICT Regulatory: Paediatrics Medicines for Children When preparing a paediatric investigation plan application, an experienced medical writer should be on hand to help interpret the requirements of the

More information

Re: Public Consultation Paper on the Regulation of Advanced Therapy Medicinal Products

Re: Public Consultation Paper on the Regulation of Advanced Therapy Medicinal Products ISCT HEAD OFFICE Suite 201 375 West 5 th Avenue Vancouver, BC Canada V5Y 1J6 Tel: 604-874-4366 Fax: 604-874-4378 isct@celltherapysociety.org www.celltherapysociety.org March 30, 2013 European Commission,

More information

Draft document circulated to Committees drafting group members 20 October Committees consultation November Adoption January 2015

Draft document circulated to Committees drafting group members 20 October Committees consultation November Adoption January 2015 28 January 2015 EMA/636600/2014 Human Medicines Research and Development Support Division Guidance on meetings with applicants on the responses to questions received from European Medicines Agency Scientific

More information

Orphan designation in the EU

Orphan designation in the EU Orphan designation in the EU EURORDIS summer school Barcelona, June 2013 Presented by: Jordi Llinares Head of Orphan Medicines An agency of the European Union Outline Overview orphan designation Procedure

More information

RAC (EU) Examination Study Checklist

RAC (EU) Examination Study Checklist RAC (EU) Examination Study Checklist Instructions: Use this checklist to track your progress when preparing for the RAC (EU) certification examination. When you begin your studying, each task statement

More information

Explanatory note on general fees payable to the European Medicines Agency

Explanatory note on general fees payable to the European Medicines Agency Explanatory note on general fees payable to the European Medicines Agency The fees, fee exemptions and definitions described in this explanatory note apply as of 1 June 2017 and are based on Council Regulation

More information

Optimising early access tools: Revision of the guidelines on Accelerated Assessment and Conditional Marketing Authorisation

Optimising early access tools: Revision of the guidelines on Accelerated Assessment and Conditional Marketing Authorisation Optimising early access tools: Revision of the guidelines on Accelerated Assessment and Conditional Marketing Authorisation High-level overview of comments received during the public consultation Presented

More information

Preparing for the withdrawal is therefore not just a matter for EU and national authorities, but also for private parties.

Preparing for the withdrawal is therefore not just a matter for EU and national authorities, but also for private parties. 19 June 2018 CMDh/361/2017, Rev.2 Questions and Answers related to the United Kingdom's withdrawal from the European Union with regard to national authorised medicinal products for human use Introduction

More information

EU Clinical Trial Regulation A view from the Industry

EU Clinical Trial Regulation A view from the Industry Conference EU Clinical Trial Regulation EU Clinical Trial Regulation A view from the Industry Judith Creba, Executive Director, EU Regulatory Strategy, Novartis Pharma AG University of Basel, Law Faculty

More information

AN INSIGHT ON ORPHAN DRUG DEVELOPMENT STRATEGY IN US AND EUROPE

AN INSIGHT ON ORPHAN DRUG DEVELOPMENT STRATEGY IN US AND EUROPE ISSN: 2230-7346 Dilip Maheshwari, et al. / JGTPS / 6(1)-(2015) 2322 2327 (Review Article) Journal of Global Trends in Pharmaceutical Sciences Journal home page: www.jgtps.com AN INSIGHT ON ORPHAN DRUG

More information

Technical Aspects of Implementation. Alastair Nixon, Chair, EFPIA ectd Focus Group, Director, Submission Standards, GSK

Technical Aspects of Implementation. Alastair Nixon, Chair, EFPIA ectd Focus Group, Director, Submission Standards, GSK Technical Aspects of Implementation Alastair Nixon, Chair, EFPIA ectd Focus Group, Director, Submission Standards, GSK 1 ectd Demonstrations 2 A shared commitment to adopt ectd Health Authorities and industry

More information

Secure, Efficient Content and Submission Lifecycle Management. QUMAS R&D Solution TM

Secure, Efficient Content and Submission Lifecycle Management. QUMAS R&D Solution TM Secure, Efficient Content and Submission Lifecycle Management QUMAS R&D Solution TM R&D Strategy Out of the Box R&D Strategy Out of the Box In an industry shaped by ever-increasing regulation, global competition

More information

IDMP update: A practical approach to IDMP implementation and the impact of the possible new phasing

IDMP update: A practical approach to IDMP implementation and the impact of the possible new phasing IDMP update: A practical approach to IDMP implementation and the impact of the possible new phasing Frits Stulp Managing Director Iperion Life Sciences Consultancy Samarind Webinar July 29th, 2015 CONTENTS

More information

Regulatory requirements for cell based medicinal products

Regulatory requirements for cell based medicinal products Regulatory requirements for cell based medicinal products 資料 3-2 Committee 25 August 2010 Dr. Bettina Klug, MSc Paul-Ehrlich-Institut, Langen klube@pei.de Paul-Ehrlich-Institut Federal Institute for Vaccines

More information

The 24 th Autumn Introductory Course: Target the Heart of European Regulatory Affairs *Preliminary Programme

The 24 th Autumn Introductory Course: Target the Heart of European Regulatory Affairs *Preliminary Programme The 24 th Autumn Introductory Course: Target the Heart of European Regulatory Affairs *Preliminary Programme Prague, Czech Republic Vienna House Andel s Prague Stroupeznickeho 21, 15000 Prague, Czech Republic

More information

EU Regulation Review: challenges and opportunities for industry

EU Regulation Review: challenges and opportunities for industry EU Regulation Review: challenges and opportunities for industry Mia Bengtström, Pharma Industry Finland Nordic Pediatric Conference June 13,2017 Paediatric Regulation Consultation: EFPIA s answers general

More information

Federal agency for medicines and health products

Federal agency for medicines and health products Federal agency for medicines and health products The implementation of the EU CT Regulation : Overview of the different projects in progress Greet Musch KCE Symposium, 12 th October 2016 1: Overview of

More information

INTRODUCTION OF FEES TO BE CHARGED BY THE EMA FOR PHARMACOVIGILANCE

INTRODUCTION OF FEES TO BE CHARGED BY THE EMA FOR PHARMACOVIGILANCE Ref. Ares(2012)723154-18/06/2012 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products authorisations, EMA Brussels, D(2012) INTRODUCTION OF FEES TO

More information

20 September 2017 EMA/90915/2016 Version 1.3 published 22 September Churchill Place Canary Wharf London E14 5EU United Kingdom

20 September 2017 EMA/90915/2016 Version 1.3 published 22 September Churchill Place Canary Wharf London E14 5EU United Kingdom 20 September 2017 EMA/90915/2016 Version 1.3 published 22 September 2017 External guidance on the implementation of the European Medicines Agency policy on the publication of clinical data for medicinal

More information

Chapter 28 Pharmaceutical acquis (human and veterinary medicinal products)

Chapter 28 Pharmaceutical acquis (human and veterinary medicinal products) Chapter 28 Pharmaceutical acquis (human and veterinary medicinal products) Screening meeting with Serbia 5 December 2014 DG SANTE D5: Medicinal products - authorisations, EMA; D6: Medicinal products -

More information

Track III: International Clinical Trials: Global Compliance Norms and EU Focus

Track III: International Clinical Trials: Global Compliance Norms and EU Focus Track III: International Clinical Trials: Global Compliance Norms and EU Focus EU Focus Emmanuelle Voisin, PhD Principal, Voisin Consulting May 2008 Rationale Clinical trials in EU important part of health

More information

AFSSAPS : Inclusion of external experts into the review process

AFSSAPS : Inclusion of external experts into the review process AFSSAPS : Inclusion of external experts into the review process Pr Philippe Lechat Director of Evaluation of Drugs and of Biological Products, AFSSAPS CHMP alternate member for France 1 AFSSAPS : Assessment

More information

The role of EMA and drug approvals for chronic HBV/HCV

The role of EMA and drug approvals for chronic HBV/HCV The role of EMA and drug approvals for chronic HBV/HCV Summit Conference Hepatitis B and C Brussels, 14-15 October 2010 Marco Cavaleri Head of Antiinfectives and Vaccines, Safety&Efficacy Sector, EMA An

More information

The 23 rd Autumn Introductory Course:

The 23 rd Autumn Introductory Course: The 23 rd Autumn Introductory Course: Target the Heart of European Regulatory Affairs Prague, Czech Republic Sheraton Prague Charles Square hotel Zitna 561/8, Prague 13-17 November 2017 Monday 13 November

More information

Regulatory update from Europe:

Regulatory update from Europe: Regulatory update from Europe: Procedures to promote early access of medicinal products to the market Elmer Schabel MD Regulatory update from Europe - Overview Current tools for early access Conditional

More information

Launching drug product in Europe Q&A

Launching drug product in Europe Q&A Launching drug product in Europe Q& David McCoubrey: Senior Regulatory ffairs Scientist, lmac Group Q& Launching drug product in Europe Q& David McCoubrey: Senior Regulatory ffairs Scientist, lmac Group

More information

Orphan designation in the EU

Orphan designation in the EU Orphan designation in the EU Workshop with Japanese Pharmaceutical Industry 19 September 2013, London Presented by: Jordi Llinares Head of Product Development Scientific Support An agency of the European

More information

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Ref. Ares(2013)2581479-05/07/2013 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products authorisations, EMA Brussels, date ENTR/6283/00 Rev 4 orphan\guidelines\format

More information

Report from the Paediatric Committee on its first anniversary

Report from the Paediatric Committee on its first anniversary European Medicines Agency London, 11 July 2008 Doc. Ref. EMEA/PDCO/347884/2008 Report from the Paediatric Committee on its first anniversary The European Medicines Agency s Paediatric Committee (PDCO)

More information

Fergus Sweeney, European Medicines Agency

Fergus Sweeney, European Medicines Agency Fergus Sweeney, European Medicines Agency Disclaimer The views presented in this presentation/these slides are those of the author and should not be understood or quoted as being made on behalf of the

More information

CTFG 10 September 2010

CTFG 10 September 2010 CTFG 10 September 2010 Clinical Trial Facilitation Group CTFG comments on the European Commission public consultation document CT3: draft detailed guidance on the collection, verification and presentation

More information

Monthly statistics report: December 2017

Monthly statistics report: December 2017 19 January 2018 EMA/39932/2018 Information Management Division Medicinal products for human use (cumulative figures for the year to date) This document provides current information related to the volume

More information

EMA s role & responsibility for the development of modern/advanced therapies

EMA s role & responsibility for the development of modern/advanced therapies EMA s role & responsibility for the development of modern/advanced therapies Agenda Current regulatory picture Overall Regulatory framework New Committee at EMA Current Activities & Challenges Egbert Flory

More information